Research
Dr. Guttman’s research made breakthrough discoveries on the immunologic basis of atopic dermatitis/eczema (AD) and alopecia areata (AA) as well as scarring alopecia. She is the first to identify in humans a distinct population of T-cells that independently produce IL-22 without co-producing IL-17 (as in mice),framing the concept that in humans,Th22 T-cells are distinct from Th17 T-cells. [5] Guttman has also designed a clinical trial that was funded by the NIH/NIAMS (UM1AR063917-01),utilizing an anti-IL-22 antibody - the first to explore the biological effects of blocking IL-22 on AD. [6] Additionally,she established the reversibility of AD and defined a series of therapeutic response-biomarkers that are now implemented in testing of novel therapeutics.
Dr. Guttman’s research identified that different AD subsets (intrinsic/extrinsic,pediatric/adult,and differences between AD patients from different racial/ethnic backgrounds) differ in their immune polarization,enabling a personalized medicine approach. [7] [8] Her lab is currently studying the contribution of specific Th2-,Th17/IL-23-,and Th22-targeting treatments to different AD phenotypes. [2]
More recently,her studies extended to other inflammatory skin diseases (alopecia areata/AA and contact dermatitis),where they have also made significant observations. They have shown that human allergic contact dermatitis is not a single entity,and various allergens (i.e.,nickel,fragrance) induce differential immune polarizations. [9] They have also redefined the molecular maps of AA,associating its molecular profile with Th1/IFN,Th2,and IL-23 activation. [10] They initiated clinical trials with specific (dupilumab,targeting only the Th2 immune pathway) or broad agents that are now identifying which cytokine pathways are pathogenic in AA.
This page is based on this
Wikipedia article Text is available under the
CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
